Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN027
MIFTS: 56

Adenomyosis

Categories: Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Adenomyosis

About this section

MalaCards integrated aliases for Adenomyosis:

Name: Adenomyosis 57 76 53
Endometriosis of Uterus 73

Characteristics:

OMIM:

57
Inheritance:
autosomal vs. x-linked dominant


Classifications:

MalaCards categories:
Global: Rare diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 57 600458
MedGen 42 C0341858
Sources

Summaries for Adenomyosis

About this section
NIH Rare Diseases : 53 Adenomyosis is a condition that affects the uterus. In women with adenomyosis, the endometrial tissue (which typically lines the uterus) moves into the outer, muscular walls of the uterus. Some women may have no signs or symptoms of the condition. When present, features of the condition include heavy menstrual bleeding, painful menstrual periods, and pelvic pain during intercourse. Some women may also develop an adenomyoma, which is a mass or growth within the uterus. The underlying cause of the condition is currently unknown. In general, treatment is based on the signs and symptoms present in each person. Forms of birth control that contain progesterone (such as birth control pills or an IUD) may decrease heavy bleeding while certain medications can be used to manage pain. In severe cases, a hysterectomy may be recommended.

MalaCards based summary : Adenomyosis, also known as endometriosis of uterus, is related to endometriosis and adenosarcoma. An important gene associated with Adenomyosis is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Innate Immune System and GPCR Pathway. The drugs Acetaminophen and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include uterus, testes and endothelial, and related phenotypes are abnormal bleeding and dysmenorrhea

OMIM : 57 Adenomyosis is characterized by the presence of endometrial glands and stroma within the myometrium. Abnormal uterine bleeding and dysmenorrhea are the most characteristic symptoms, occurring in approximately 65% of cases (Arnold et al., 1995). (600458)

Wikipedia : 76 Adenomyosis is a gynecologic medical condition characterized by the abnormal presence of endometrial... more...

Sources

Related Diseases for Adenomyosis

About this section

Diseases related to Adenomyosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 192)
# Related Disease Score Top Affiliating Genes
1 endometriosis 31.7 ESR1 PGR VEGFA
2 adenosarcoma 30.8 ESR1 PGR
3 endometrial adenocarcinoma 30.7 ESR1 PGR VEGFA
4 endometrial stromal sarcoma 30.3 ESR1 OXTR PGR
5 endometriosis of ovary 30.3 ESR1 PGR
6 ovarian cyst 29.5 MUC16 PRL VEGFA
7 endometrial cancer 29.1 ESR1 MMP2 MMP9 PGR TIMP2 VEGFA
8 breast cancer 24.8 ESR1 MMP1 MMP2 MMP9 PGR PRL
9 uterine anomalies 11.3
10 endometriosis of uterus 11.1
11 vulvar syringoma 10.8 ESR1 PGR
12 lung leiomyoma 10.8 ESR1 PGR
13 vestibular gland benign neoplasm 10.8 ESR1 PGR
14 bartholin's gland adenoma 10.8 ESR1 PGR
15 glassy cell carcinoma of the cervix 10.8 ESR1 PGR
16 extracranial arteriovenous malformation 10.8 MMP2 MMP9
17 vulvar benign neoplasm 10.8 ESR1 PGR
18 trigonitis 10.8 ESR1 PGR
19 vulvar leiomyoma 10.8 ESR1 PGR
20 pancreatic serous cystadenoma 10.8 PGR VEGFA
21 angiokeratoma circumscriptum 10.8 MMP9 VEGFA
22 predominantly cortical thymoma 10.8 ESR1 PGR
23 focal myositis 10.8 MMP2 MMP9
24 breast medullary carcinoma 10.8 ESR1 PGR
25 breast scirrhous carcinoma 10.8 ESR1 PGR
26 lentigo maligna melanoma 10.8 MMP2 MMP9
27 villous adenocarcinoma 10.8 MMP2 MMP9
28 progesterone resistance 10.8 ESR1 PGR
29 psammomatous meningioma 10.8 MMP2 MMP9
30 progesterone-receptor positive breast cancer 10.8 ESR1 PGR
31 cribriform carcinoma 10.8 ESR1 PGR
32 acute transverse myelitis 10.8 MMP2 MMP9
33 oncocytic breast carcinoma 10.8 ESR1 PGR
34 endometrial squamous cell carcinoma 10.7 ESR1 PGR
35 gastric signet ring cell adenocarcinoma 10.7 ESR1 PGR
36 senile ectropion 10.7 MMP2 MMP9
37 endometrial mucinous adenocarcinoma 10.7 ESR1 PGR
38 adenoid basal cell carcinoma 10.7 ESR1 PGR
39 apocrine adenocarcinoma 10.7 ESR1 PGR
40 gender identity disorder 10.7 ESR1 PGR
41 bartholin's gland benign neoplasm 10.7 ESR1 PGR
42 deep angioma 10.7 ESR1 PGR
43 synchronous bilateral breast carcinoma 10.7 ESR1 PGR
44 sick building syndrome 10.7 MMP9 VEGFA
45 adamantinous craniopharyngioma 10.7 MMP9 VEGFA
46 ischemic colitis 10.7 MMP2 MMP9
47 parotitis 10.7 MMP2 MMP9
48 breast adenoid cystic carcinoma 10.7 ESR1 PGR
49 cervical carcinosarcoma 10.7 ESR1 PGR
50 estrogen excess 10.7 ESR1 PGR

Graphical network of the top 20 diseases related to Adenomyosis:



Diseases related to Adenomyosis
Sources

Symptoms & Phenotypes for Adenomyosis

About this section

Symptoms via clinical synopsis from OMIM:

57
GU:
adenomyosis

Lab:
endometrial glands and stroma within the myometrium
abnormal uterine bleeding
dysmenorrhea


Clinical features from OMIM:

600458

Human phenotypes related to Adenomyosis:

32
# Description HPO Frequency HPO Source Accession
1 abnormal bleeding 32 HP:0001892
2 dysmenorrhea 32 HP:0100607
3 abnormality of the genitourinary system 32 HP:0000119

MGI Mouse Phenotypes related to Adenomyosis:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.16 ESR1 MMP1 MMP2 MMP3 MMP9 PGR
2 immune system MP:0005387 10.13 MMP9 PGR PRL PTGS2 TIMP2 VEGFA
3 behavior/neurological MP:0005386 10.11 ESR1 MMP9 OXTR PGR PRL PTGS2
4 hematopoietic system MP:0005397 10.08 ESR1 MMP2 MMP3 MMP9 PGR PTGS2
5 cardiovascular system MP:0005385 10.04 ESR1 MMP2 MMP9 PGR PTGS2 TIMP2
6 integument MP:0010771 9.95 ESR1 MMP9 OXTR PGR PRL PTGS2
7 neoplasm MP:0002006 9.92 ESR1 MMP1 MMP2 MMP9 PGR PRL
8 muscle MP:0005369 9.91 ESR1 MMP2 MMP9 OXTR PGR PTGS2
9 nervous system MP:0003631 9.91 PTGS2 TIMP2 VEGFA ESR1 MMP2 MMP3
10 normal MP:0002873 9.7 TIMP2 VEGFA ESR1 MMP2 OXTR PGR
11 reproductive system MP:0005389 9.5 ESR1 MMP9 OXTR PGR PRL PTGS2
12 skeleton MP:0005390 9.17 PGR PTGS2 VEGFA ESR1 MMP2 MMP3
Sources

Drugs & Therapeutics for Adenomyosis

About this section

Drugs for Adenomyosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Ibuprofen Approved Phase 4 15687-27-1 3672
3
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
4 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
5 Analgesics Phase 4,Phase 3
6 Analgesics, Non-Narcotic Phase 4
7 Anti-Inflammatory Agents Phase 4,Not Applicable
8 Anti-Inflammatory Agents, Non-Steroidal Phase 4
9 Antipyretics Phase 4
10 Antirheumatic Agents Phase 4
11 Cyclooxygenase Inhibitors Phase 4
12 Ramosetron Approved, Investigational Phase 3 132036-88-5
13
Goserelin Approved Phase 2, Phase 3 65807-02-5 47725 5311128
14
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
15
Lactitol Investigational Phase 2, Phase 3 585-86-4 3871
16 Antiemetics Phase 3,Not Applicable
17 Autonomic Agents Phase 3,Not Applicable
18 Gastrointestinal Agents Phase 3,Not Applicable
19 Neurotransmitter Agents Phase 3,Phase 1
20 Serotonin Agents Phase 3
21 Serotonin Antagonists Phase 3
22 Estrogens Phase 2, Phase 3,Not Applicable,Early Phase 1
23 Hormone Antagonists Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
24 Hormones Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
26 Antineoplastic Agents, Hormonal Phase 2, Phase 3,Not Applicable
27 Aromatase Inhibitors Phase 2, Phase 3
28 Estrogen Antagonists Phase 2, Phase 3
29 Steroid Synthesis Inhibitors Phase 2, Phase 3
30 Micronutrients Phase 3
31 Trace Elements Phase 3
32
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
33
Levonorgestrel Approved, Investigational Phase 2,Not Applicable,Early Phase 1 797-63-7, 17489-40-6 13109
34
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
35
Ropivacaine Approved Phase 2 84057-95-4 71273 175805
36 Contraceptive Agents Phase 2,Not Applicable,Early Phase 1
37 Contraceptives, Oral Phase 2,Not Applicable,Early Phase 1
38 Contraceptives, Oral, Combined Phase 2,Not Applicable,Early Phase 1
39 Anesthetics Phase 2,Not Applicable
40 Anesthetics, Local Phase 2
41 Anti-Arrhythmia Agents Phase 2
42 Central Nervous System Depressants Phase 2
43 Diuretics, Potassium Sparing Phase 2,Early Phase 1
44 Sodium Channel Blockers Phase 2
45
Bromocriptine Approved, Investigational Phase 1 25614-03-3 31101
46
Dopamine Approved Phase 1 51-61-6, 62-31-7 681
47 Antiparkinson Agents Phase 1
48 Dopamine Agents Phase 1
49 Dopamine agonists Phase 1
50
Estradiol Approved, Investigational, Vet_approved Not Applicable,Early Phase 1 50-28-2 5757

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
2 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
3 Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy Unknown status NCT01483417 Phase 3
4 The Use of Doppler to Diagnose Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
5 Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01048931 Phase 3
6 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
7 Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis Completed NCT01218581 Phase 2, Phase 3 received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
8 Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
9 Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Recruiting NCT03520439 Phase 2, Phase 3 Mifepristone;Placebo
10 Efficacy of Trace Elements in the Treatment of Endometriosis: a Pilot Study Active, not recruiting NCT02437175 Phase 3
11 LNG-IUS for Treatment of Dysmenorrhea Completed NCT01601366 Phase 2 Combined oral contraceptives
12 Tactile Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding Completed NCT02248194 Phase 2
13 Superior Hypogastric Nerve Block for Pain Control Post-UFE Completed NCT02270255 Phase 2 0.75% Ropivacaine;1% Xylocaine
14 Adenomyosis and Ulipristal Acetate Recruiting NCT02587000 Phase 2 Ulipristal acetate;Placebo
15 Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis Withdrawn NCT02794467 Phase 2 Epelsiban;Placebo
16 Vaginal Bromocriptine for Treatment of Adenomyosis Completed NCT01821001 Phase 1 Vaginal Bromocriptine
17 Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis Unknown status NCT01259180 Not Applicable
18 Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis Unknown status NCT00172588
19 Proliferation of Endometrial Stromal Cells in Adenomyosis Unknown status NCT00173212
20 Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Unknown status NCT02556411 Not Applicable LNG-IUS 13,5 mg Levonorgestrel;Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
21 Health-Related QoL Among Women Receiving Hysterectomy in NTUH Unknown status NCT00155870
22 Progestin Treatment for Endometrial Stromal Cells in Adenomyosis Unknown status NCT00155051
23 To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01564602 Not Applicable
24 The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone (AMH) Unknown status NCT00928044
25 Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy Unknown status NCT01289314 Not Applicable
26 Histopathological Diagnosis of Adenomyosis Completed NCT02340533 Not Applicable
27 Norwegian Adenomyosis Study I Completed NCT02201719
28 Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis Completed NCT03027648 Not Applicable
29 Levonorgestrel Intrauterine System and Adenomyosis Completed NCT03104309 Not Applicable
30 New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma Completed NCT02997787
31 What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Completed NCT01992718 Early Phase 1
32 Use of Dexamethasone in Uterine Artery Embolization Completed NCT02056717 Not Applicable Dexamethasone;Normal saline
33 Uterine Artery Embolization for Symptomatic Fibroids Completed NCT00354471
34 Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Completed NCT02192606 Not Applicable
35 Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy Completed NCT01806012 Not Applicable
36 AMH Levels Change During Treatment With GnRh Agonist Completed NCT02086279 Not Applicable GnRH analogue
37 Magnetic Resonance Imaging (MRI) Hysterosalpingography Versus Radiographic Hysterosalpingography in Female Infertility Completed NCT02108665 Not Applicable
38 Surgical Success After Laparoscopic vs Abdominal Hysterectomy Completed NCT01793584 Not Applicable
39 Electronic Catheter Stethoscope Completed NCT01463462
40 Sonohysterography , 3D Ultrasonography and Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility Completed NCT02399501 Not Applicable
41 The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms Recruiting NCT02495311
42 Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Recruiting NCT03037944 Early Phase 1 Yasmin
43 Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis Recruiting NCT03302468
44 Cooperative Adenomyosis Network Recruiting NCT03230994
45 Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Recruiting NCT02914704 Not Applicable
46 Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Recruiting NCT02086344 Not Applicable
47 Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis Recruiting NCT03006406 Not Applicable Long term GnRH-a (3.75mg)
48 Acceptability and Tolerance of Hysteroscopy and Hysterosonography in Consultation Recruiting NCT03121560 Not Applicable
49 Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Active, not recruiting NCT02197923
50 Effect of Salpingectomy During Conservative Hysterectomy Active, not recruiting NCT01628432 Not Applicable

Search NIH Clinical Center for Adenomyosis

Sources

Genetic Tests for Adenomyosis

About this section
Sources

Anatomical Context for Adenomyosis

About this section

MalaCards organs/tissues related to Adenomyosis:

41
Uterus, Testes, Endothelial, Pituitary, Brain, Smooth Muscle, Monocytes
Sources

Publications for Adenomyosis

About this section

Articles related to Adenomyosis:

(show top 50) (show all 768)
# Title Authors Year
1
Endometriosis and adenomyosis are associated with increased risk of preterm delivery and a small-for-gestational-age child: a systematic review and meta-analysis. ( 29753309 )
2018
2
Clinical Usefulness of the Microbubble Contrast Agent SonoVue in Enhancing the Effects of High-Intensity Focused Ultrasound for the Treatment of Adenomyosis. ( 29689636 )
2018
3
Fertility-Sparing Treatment of Adenomyosis in Patients With Infertility: A Systematic Review of Current Options. ( 29402199 )
2018
4
Adenomyosis and urinary system symptoms. ( 29655132 )
2018
5
ILK-induced epithelial-mesenchymal transition promotes the invasive phenotype in adenomyosis. ( 29409901 )
2018
6
The Investigation and Management of Adenomyosis in Women Who Wish to Improve or Preserve Fertility. ( 29736395 )
2018
7
Operation, hormone therapy and recovery of the patients with severe forms of adenomyosis. ( 29447009 )
2018
8
Reproductive Outcomes after Fertility-Sparing Surgery for Focal and Diffuse Adenomyosis: a Systematic Review. ( 29305234 )
2018
9
Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? ( 29893860 )
2018
10
The Effect of Adenomyosis in Myometrial Invasion and Overall Survival in Endometrial Cancer. ( 29040186 )
2018
11
Drug Development in Endometriosis and Adenomyosis: It Takes More Than Just Good Science. ( 29962279 )
2018
12
The Risk of Preterm Births Among Pregnant Women With Adenomyosis. ( 29363150 )
2018
13
Effects of pelvic endometriosis and adenomyosis on ciliary beat frequency and muscular contractions in the human fallopian tube. ( 29753325 )
2018
14
Adenomyosis and Endometrial Cancer: Literature Review. ( 29874641 )
2018
15
GnRH agonist improves pregnancy outcome in mice with induced adenomyosis by restoring endometrial receptivity. ( 29922037 )
2018
16
The expression of MA1llerian inhibiting substance/anti-MA1llerian hormone type II receptor in myoma and adenomyosis. ( 29372159 )
2018
17
Re: Pregnancy outcomes in patients with uterine fibroids treated with ultrasound-guided high-intensity focused ultrasound Is the noninvasive nature of HIFU ablation for uterine fibroids and adenomyosis setting patients up for future operative delivery? ( 29405613 )
2018
18
Transvaginal Elastosonography as an Imaging Technique for Diagnosing Adenomyosis. ( 29320956 )
2018
19
The Possible Role of Eukaryotic Translation Initiation Factor 3 Subunit e (eIF3e) in the Epithelial-Mesenchymal Transition in Adenomyosis. ( 29871559 )
2018
20
A sonographic classification and reporting system for diagnosing adenomyosis. ( 29790217 )
2018
21
Combination therapeutic effects of high intensity focused ultrasound and Metformin for the treatment of adenomyosis. ( 29434812 )
2018
22
Evaluation of NovaSure<sup>Ar</sup> global endometrial ablation in symptomatic adenomyosis: A longitudinal study with a 36 month follow-up. ( 29886317 )
2018
23
Anterior Focal Adenomyosis and Bladder Deep Infiltrative: is There a Link? ( 29432902 )
2018
24
Accuracy and Reproducibility of Sonoelastography for the Assessment of Fibroids and Adenomyosis, with Magnetic Resonance Imaging as Reference Standard. ( 29784438 )
2018
25
A clinical audit on the efficacy and safety of uterine artery embolisation for symptomatic adenomyosis: Results in 117 women. ( 29344938 )
2018
26
Endophytic-Type Endometrial Cancer with Adenomyosis Successfully Diagnosed with Hysteroscopic Endometrial Biopsy Using an 8.3-mm Operative Resectoscope: A Case Report. ( 29928209 )
2018
27
Uterine adenomyosis and adenomyoma: the surgical approach. ( 29566853 )
2018
28
Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas. ( 29626678 )
2018
29
Long-term dienogest administration in patients with symptomatic adenomyosis. ( 29845696 )
2018
30
Conservative surgery of diffuse adenomyosis with TOUA: Single surgeon experience of one hundred sixteen cases and report of fertility outcomes. ( 29699636 )
2018
31
Positive associations between upregulated levels of stress-induced phosphoprotein 1 and matrix metalloproteinase-9 in endometriosis/adenomyosis. ( 29304094 )
2018
32
Berberine inhibits growth and inflammatory invasive phenotypes of ectopic stromal cells: Imply the possible treatment of adenomyosis. ( 29752208 )
2018
33
Associations between a single nucleotide polymorphism of stress-induced phosphoprotein 1 and endometriosis/adenomyosis. ( 29673672 )
2018
34
Conservative surgery of uterine adenomyosis via laparoscopic versus laparotomic approach in a single institution. ( 29845687 )
2018
35
Re: A comparison of the cost-utility of ultrasound-guided high-intensity focused ultrasound and hysterectomy for adenomyosis: a retrospective study Is the cost-effectiveness of HIFU for adenomyosis and fibroids feasible? ( 29405542 )
2018
36
Effect of pretreatment with gonadotropin-releasing hormone analog GnRH-I+ on high-intensity focused ultrasound ablation for diffuse adenomyosis: a preliminary study. ( 29447020 )
2018
37
Experience of Symptoms and Disease Impact in Patients with Adenomyosis. ( 29197944 )
2017
38
Changes in anti-mA1llerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid. ( 28856867 )
2017
39
Abnormal expression of Nrf2 may play an important role in the pathogenesis and development of adenomyosis. ( 28817677 )
2017
40
Decreased expression of interleukin-37 in the ectopic and eutopic endometria of patients with adenomyosis. ( 28762845 )
2017
41
Rhein ameliorates adenomyosis by inhibiting NF-I_B and I^-Catenin signaling pathway. ( 28763746 )
2017
42
Ultrasound-guided transcervical radiofrequency ablation for symptomatic uterine adenomyosis. ( 27792415 )
2017
43
Quercetin alleviates generalized hyperalgesia in mice with induced adenomyosis. ( 28849202 )
2017
44
Serum Osteopontin Levels Are Decreased in Focal Adenomyosis. ( 27678100 )
2017
45
[Discussion on the acupuncture and moxibustion thoughts of diagnosis and treatment for secondary dysmenorrhea of adenomyosis on the basis of disease location and pathogenesis]. ( 29354982 )
2017
46
Transvaginal Ultrasound for the Diagnosis of Adenomyosis: Systematic Review and Meta-Analysis. ( 28864044 )
2017
47
Immunohistochemical Parameters of Musashi-1 in Nodular and Diffuse Adenomyosis. ( 28853072 )
2017
48
New paradigms in the conservative surgical and interventional management of adenomyosis. ( 28665807 )
2017
49
Downregulation of DNA methyltransferase 3 alpha promotes cell proliferation and invasion of ectopic endometrial stromal cells in adenomyosis. ( 27986572 )
2017
50
Safety of ultrasound-guided high-intensity focused ultrasound ablation for diffuse adenomyosis: A retrospective cohort study. ( 28069193 )
2017
Sources

Variations for Adenomyosis

About this section
Sources

Expression for Adenomyosis

About this section
Search GEO for disease gene expression data for Adenomyosis.
Sources

Pathways for Adenomyosis

About this section

Pathways related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.85 MMP1 MMP2 MMP3 MMP9 MUC16 PRL
2
GPCR Pathway 64
Show member pathways
 13.56 ESR1 MMP1 MMP2 MMP3 MMP9 PTGS2
3
Cytokine Signaling in Immune system 66
Show member pathways
 13.19 MMP1 MMP2 MMP3 MMP9 PRL PTGS2
4
Circadian entrainment 37
Show member pathways
 12.86 ESR1 MMP1 MMP2 MMP9 PGR VEGFA
5
Pathways in cancer 37
12.65 ESR1 MMP1 MMP2 MMP9 PTGS2 VEGFA
6
Glioma 37
Show member pathways
 12.63 ESR1 MMP2 MMP9 VEGFA
7
Degradation of the extracellular matrix 66
Show member pathways
 12.6 MMP1 MMP2 MMP3 MMP9 TIMP2
8
IL-17 Family Signaling Pathways 65
Show member pathways
 12.22 MMP1 MMP3 MMP9 PTGS2
9
Proteoglycans in cancer 37
12.18 ESR1 MMP2 MMP9 VEGFA
10
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.08 MMP1 MMP3 VEGFA
11
Integrated Breast Cancer Pathway 1
12.02 ESR1 MMP1 VEGFA
12
Colorectal Cancer Metastasis 64
12.02 MMP1 MMP2 MMP9 PTGS2 VEGFA
13
Fluid shear stress and atherosclerosis 37
11.96 MMP2 MMP9 VEGFA
14
Adhesion 4
11.89 MMP2 MMP3 MMP9
15
Signaling by ERBB4 66
Show member pathways
 11.83 ESR1 PGR PRL
16
TNF signaling pathway 37
11.83 MMP3 MMP9 PTGS2
17
Rheumatoid arthritis 37
11.74 MMP1 MMP3 VEGFA
18
Matrix Metalloproteinases 1
Show member pathways
 11.72 MMP1 MMP2 MMP3 MMP9 TIMP2
19
Bladder cancer 37 1
11.6 MMP1 MMP2 MMP9 VEGFA
20
Angiogenesis (CST) 4
11.6 MMP2 MMP3 MMP9 PTGS2 TIMP2
21
Celecoxib Pathway, Pharmacodynamics 61
11.54 MMP9 PTGS2 VEGFA
22
Interleukin-4 and 13 signaling 66
11.49 MMP1 MMP2 MMP3 MMP9 PTGS2 VEGFA
23
Hepatitis C and Hepatocellular Carcinoma 1
11.45 MMP1 PTGS2 VEGFA
24
Aryl Hydrocarbon Receptor 1
11.42 ESR1 PTGS2 VEGFA
25
Cell adhesion_ECM remodeling 22
11.34 MMP1 MMP2 MMP3 MMP9 TIMP2
26
Cell adhesion_Cell-matrix glycoconjugates 22
11.26 MMP1 MMP3 MMP9 TIMP2
27
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.23 MMP1 MMP2 MMP9
28
Prostaglandin Synthesis and Regulation 1
11.15 PRL PTGS2
29
Plasma membrane estrogen receptor signaling 1
11.09 ESR1 MMP2 MMP9
30
IL1 and megakaryocytes in obesity 1
11.06 MMP9 TIMP2
31
Angiogenesis (WikiPathways) 1
11.03 MMP9 TIMP2 VEGFA
32
A-beta Pathways: Plaque Formation and APP Metabolism 65
11.02 MMP2 MMP9
33
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 66
10.97 MMP1 MMP2
34
Immune response_Oncostatin M signaling via JAK-Stat in human cells 22
10.92 MMP1 VEGFA
35
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 10.9 MMP1 MMP2 MMP3 MMP9 PTGS2 VEGFA
36
Syndecan-1-mediated signaling events 1
10.86 MMP1 MMP9
Sources

GO Terms for Adenomyosis

About this section

Cellular components related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 MMP2 MMP3 MMP9 MUC16 PRL TIMP2
2 extracellular region GO:0005576 9.56 MMP1 MMP2 MMP3 MMP9 MUC16 PRL
3 extracellular matrix GO:0031012 9.02 MMP1 MMP2 MMP3 MMP9 TIMP2

Biological processes related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 response to estradiol GO:0032355 9.58 ESR1 OXTR PTGS2
2 response to cytokine GO:0034097 9.54 OXTR PTGS2 TIMP2
3 endodermal cell differentiation GO:0035987 9.51 MMP2 MMP9
4 lactation GO:0007595 9.5 OXTR PRL VEGFA
5 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.49 OXTR PTGS2
6 macrophage differentiation GO:0030225 9.48 MMP9 VEGFA
7 mammary gland alveolus development GO:0060749 9.46 ESR1 VEGFA
8 collagen catabolic process GO:0030574 9.46 MMP1 MMP2 MMP3 MMP9
9 positive regulation of protein oligomerization GO:0032461 9.43 MMP1 MMP3
10 embryo implantation GO:0007566 9.43 MMP2 MMP9 PTGS2
11 cytokine-mediated signaling pathway GO:0019221 9.43 MMP1 MMP2 MMP3 MMP9 PTGS2 VEGFA
12 extracellular matrix disassembly GO:0022617 9.02 MMP1 MMP2 MMP3 MMP9 TIMP2

Molecular functions related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 9.97 ESR1 MMP1 MMP2 MMP3 MMP9 PGR
2 peptidase activity GO:0008233 9.71 MMP1 MMP2 MMP3 MMP9
3 serine-type endopeptidase activity GO:0004252 9.56 MMP1 MMP2 MMP3 MMP9
4 endopeptidase activity GO:0004175 9.5 MMP1 MMP3 MMP9
5 metallopeptidase activity GO:0008237 9.46 MMP1 MMP2 MMP3 MMP9
6 metalloendopeptidase activity GO:0004222 9.26 MMP1 MMP2 MMP3 MMP9
7 zinc ion binding GO:0008270 9.17 ESR1 MMP1 MMP2 MMP3 MMP9 PGR
Sources

Sources for Adenomyosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....